Harrow Health, Inc.
Financials
Valuation Metrics
Harrow Health, Inc.'s Market Cap is $1.05B. At end of 2025 it was $1.80B. Ranked #2383 of 3,118 in US market (top 76%), #964 of 1,474 on NASDAQ (top 65%), #176 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 66%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.05B | US#2,383/3,118 Sec#176/265 |
| Revenue | $276M | US#2,460/3,118 Sec#101/265 |
| Net Income | $-37M | US—/3,118 Sec—/265 |
| Total Assets | $417M | US#2,824/3,118 Sec#179/265 |
| Net Assets | $15M | US#2,888/3,118 Sec#232/265 |
| Employees | 373 | US#2,347/3,118 Sec#97/265 |
| Value | ||
| P/B | 69.16x | US#2,888/3,118 Sec#230/265 |
| P/S | 3.81x | US#2,027/3,118 Sec#64/265 |
| EV/EBITDA | 282.85x | US#2,483/3,118 Sec#83/265 |
| FCF Yield | 0.54% | US#2,207/3,118 Sec#84/265 |
| Profitability | ||
| ROA | -8.93% | US#2,631/3,118 Sec#99/265 |
| Op. Margin | 2.07% | US#2,212/3,118 Sec#75/265 |
| Revenue Growth | 21.05% | US#642/3,118 Sec#73/265 |
| Financial Health | ||
| Debt Ratio | 2644.55% | US#2,870/3,118 Sec#233/265 |
| Total Debt | $301M | US#2,083/3,118 Sec#77/265 |
| FCF | $6M | US#2,247/3,118 Sec#84/265 |
| Cash | $84M | US#2,319/3,118 Sec#185/265 |
| Current Ratio | 2.24x | US#1,089/3,118 Sec#214/265 |
| Net Debt/EBITDA | 48.37x | US#2,515/3,118 Sec#85/265 |
| Performance | ||
| 1Y Return | -25.34% | US#2,499/3,118 Sec#198/265 |
| 1M Return | -7.48% | US#2,372/3,118 Sec#171/265 |
| From 52W High | -48.59% | US#2,584/3,118 Sec#193/265 |
| 1Y MDD | -50.29% | US#2,406/3,118 Sec#165/265 |
| Trading | ||
| Volume | 616,296 shares | US#2,347/3,118 Sec#225/265 |
| Trading Value | $17M | US#2,314/3,118 Sec#180/265 |
| Per Share | ||
| EPS | $-1.00 | US—/3,118 Sec—/265 |
| BPS | $0.41 | US#2,752/3,118 Sec#219/265 |
Company Info
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.